Flutamide
- Generic Name
- Flutamide
- Brand Names
- Eulexin
- Drug Type
- Small Molecule
- Chemical Formula
- C11H11F3N2O3
- CAS Number
- 13311-84-7
- Unique Ingredient Identifier
- 76W6J0943E
- Background
An antiandrogen with about the same potency as cyproterone in rodent and canine species.
- Indication
For the management of locally confined Stage B2-C and Stage D2 metastatic carcinoma of the prostate
- Associated Conditions
- Stage B2-C metastatic Carcinoma of the Prostate, Stage D2 metastatic Carcinoma of the Prostate
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- Drug: Luteinizing hormone releasing hormone [LHRH] agonistRadiation: Radiation therapy
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 397
- Registration Number
- NCT00004054
- Locations
- 🇺🇸
Lutheran General Cancer Care Center, Park Ridge, Illinois, United States
🇺🇸Greater Baltimore Medical Center and Cancer Center, Baltimore, Maryland, United States
🇺🇸Kimmel Cancer Center at Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States
Hormone Therapy in Treating Patients With Advanced Prostate Cancer
- Conditions
- Prostate Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-07-02
- Target Recruit Count
- 966
- Registration Number
- NCT00003026
- Locations
- 🇳🇱
St. Elisabeth Ziekenhuis, Tilburg, Netherlands
🇳🇱Academisch Ziekenhuis Groningen, Groningen, Netherlands
🇬🇧City General Hospital, Stoke-On-Trent, England, United Kingdom
Adjuvant Radiation Therapy Plus Hormone Therapy Compared With Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- Procedure: adjuvant therapyRadiation: radiation therapyDrug: releasing hormone agonist therapy
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 67
- Registration Number
- NCT00023829
- Locations
- 🇨🇦
Toronto Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada
S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-07-16
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 41
- Registration Number
- NCT00028769
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸CCOP - Atlanta Regional, Atlanta, Georgia, United States
🇺🇸CCOP - Central Illinois, Decatur, Illinois, United States
Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer
- Conditions
- Adenocarcinoma of the ProstateStage III Prostate CancerStage IV Prostate CancerRecurrent Prostate Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-07-10
- Lead Sponsor
- Burzynski Research Institute
- Registration Number
- NCT00003517
- Locations
- 🇺🇸
Burzynski Clinic, Houston, Texas, United States
Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia
- Conditions
- Congenital Adrenal Hyperplasia (CAH)
- Interventions
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- Target Recruit Count
- 62
- Registration Number
- NCT00001521
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.